Sensei Biotherapeutics Inc (SNSE)

Apr 2, 2025, 7:30 AM EDT - 9 days ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 14 days ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 15 days ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 2 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 3 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 4 months ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 5 months ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 7 months ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 7 months ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 11 months ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 1 year ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 7, 2023, 5:15 PM EST - 2 years ago

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Mar 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 21, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Feb 16, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 14, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Feb 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

Jan 5, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

Dec 12, 2022, 11:42 AM EST - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)

CME

Dec 8, 2022, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Provides Update on Strategic Priorities